Hemodynamic effects of anesthesia in patients chronically treated with angiotensin-converting enzyme inhibitors

P Colson1, M Saussine, J R Séguin

  • 1Department of Anesthesiology, Centre Hospitalo-Universitaire, Montpellier, France.

Insights

Patients on angiotensin-converting enzyme inhibitors (ACEIs) experience greater blood pressure drops during anesthesia induction. Prompt fluid resuscitation and vasopressors effectively managed these hemodynamic changes in ACEI-treated patients.

Area of Science:

  • Anesthesiology
  • Cardiovascular Pharmacology
  • Critical Care Medicine

Background:

  • Angiotensin-converting enzyme inhibitors (ACEIs) are widely used for cardiovascular disease.
  • Emerging reports suggest potential hemodynamic risks, including hypotension and bradycardia, when ACEIs are combined with anesthesia.
  • This necessitates a closer examination of anesthetic effects in patients on chronic ACEI therapy.

Purpose of the Study:

  • To evaluate the hemodynamic impact of anesthesia induction in hypertensive patients on chronic ACEI treatment.
  • To compare these effects against a control group receiving other antihypertensive medications.

Main Methods:

  • A comparative study involving 16 hypertensive patients undergoing major surgery.
  • Eight patients were on chronic ACEI therapy (ACEI group); eight received other antihypertensives (control group).
  • Anesthesia induction involved flunitrazepam, fentanyl, and pancuronium, with hemodynamic parameters monitored.

Main Results:

  • Anesthesia induction caused significant mean arterial blood pressure decrease in both groups, more pronounced in the ACEI group (33.5% vs. 16.8%).
  • ACEI patients showed significant reductions in pulmonary capillary wedge pressure and cardiac index.
  • Hemodynamic stability was rapidly restored in ACEI patients with fluid administration and, in some cases, phenylephrine.

Conclusions:

  • Anesthesia induction leads to more significant hypotension in patients chronically treated with ACEIs.
  • Pulmonary capillary wedge pressure and cardiac index reductions are key hemodynamic changes in ACEI-treated patients during induction.
  • Careful hemodynamic monitoring and prompt management strategies are crucial for patients on ACEIs undergoing anesthesia.

Related Concept Videos

Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...